Biotech innovator EVerZom has raised €10 million to advance the development of its exosome-based regenerative medicine therapies, aiming to bring next-generation treatments to patients and strengthen its position as a European leader in tissue repair and organ regeneration.
The round was led by Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by Audacia, and Aloe Private Equity, with participation from Paris Business Angels, Capital Cell, and several family offices.
Advancing Toward Clinical Trials
EverZom will use the funding to:
- Launch its first clinical trial of EverGel in 2026, targeting Crohn’s complex perianal fistulas.
- Expand research into new therapeutic areas, including hepatology and dermatology.
- Scale and industrialize its GMP-compliant exosome production platform to support future clinical and commercial programs.
Led by CEO and co-founder Jeanne Volatron, the startup develops mesenchymal stem cell–derived exosome therapies using a proprietary bioproduction and biomaterial integration platform that enhances the regenerative potential of exosomes.
“This fundraising marks a decisive milestone for EverZom,” said Jeanne Volatron. “Our mission is to unlock the therapeutic power of exosomes for patients with severe, unmet medical needs. With this support, we’ll deliver our first clinical proof of concept and build the foundation for an industrial platform driving a new class of regenerative treatments.”
Advertisement
Building a Pipeline of Regenerative Solutions
EverZom’s therapeutic pipeline includes:
- EverGel – targeting Crohn’s complex perianal fistulas (clinical trials starting 2026).
- Eviv – for acute-on-chronic liver failure (ACLF), currently in preclinical development.
- Exploratory programs – in ophthalmology, regenerative dermatology, and non-pharma applications such as cosmetics and veterinary medicine.
The company’s exosome technology combines biological precision with scalable manufacturing — a key advantage in advancing regenerative therapies from lab to clinic.
About EverZom
Founded in 2019, EverZom is a Strasbourg-based biotechnology company pioneering exosome-based therapies for tissue repair, regeneration, and organ healing. Its multi-patented platform covers sourcing, production, and formulation of exosomes for proprietary and partnered programs. Recognized by the European EIC Accelerator, EverZom is driving innovation at the intersection of cell therapy, nanotechnology, and biomanufacturing to redefine the future of regenerative medicine.
